Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma

Head and Neck

Volumn 35, Issue 1, 2013, Pages 76-85

  Xie, Wen ^a   Aisner, Seena ^b   Baredes, Soly ^b   Sreepada, Gangadhar ^b   Shah, Rasesh ^b   Reiss, Michael ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

head and neck cancer; immunohistochemistry; Smad; tissue microarray; transforming growth factor

Indexed keywords

SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD PROTEINS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871181384     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22924     Document Type: Article

References (42)

1. Jemal A, Center MM, DeSantis C, Ward EM,. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-1907.
2. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Xie W, Reiss M,. Alterations of transforming growth factor-β signaling in squamous cell carcinomas. In:, Glick AB, Van Waes C, editors. Signaling pathways in squamous cancer. New York: Springer; 2011. pp 53-90.
4. Cui W, Fowlis DJ, Bryson S, et al. TGFβ1 inhibits the formation of benign skin tumours but enhances progression to invasive spindle cell carcinnomas in transgenic mice. Cell 1996; 86: 531-542. (Pubitemid 26299485)
5. Oft M, Heider KH, Beug H,. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8: 1243-1252. (Pubitemid 28540052)
6. Wrana JL, Attisano L, Carcamo J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-1014.
7. Wrana JL, Tran H, Attisano L, et al. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol Cell Biol 1994; 14: 944-950. (Pubitemid 24036544)
8. Yamashita H, ten Dijke P, Franzen P, Miyazono K, Heldin CH,. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta. J Biol Chem 1994; 269: 20172-20178. (Pubitemid 24250943)
9. Attisano L, Wrana JL,. Signal transduction by the TGF-beta superfamily. Science 2002; 296: 1646-1647.
10. Miyazono K,. TGF-beta receptors and signal transduction. Int J Hematol 1997; 65: 97-104.
11. Shi Y, Massague J,. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700. (Pubitemid 36724933)
12. ten Dijke P, Miyazono K, Heldin CH,. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol 1996; 8: 139-145. (Pubitemid 26109085)
13. Kareddula A, Zachariah E, Notterman D, Reiss M,. Transforming growth factor-β signaling strength determines target gene expression profile in human keratinocytes. J Epithel Biol Pharmacol 2008; 1: 40-94.
14. Massague J,. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
15. Fynan TM, Reiss M,. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993; 4: 493-540.
16. Reiss M, Stash EB,. High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor beta. Cancer Commun 1990; 2: 363-369.
17. Yan W, Vellucci VF, Reiss M,. Smad protein expression and activation in transforming growth factor-beta refractory human squamous cell carcinoma cells. Oncol Res 2000; 12: 157-167.
18. Bharathy S, Xie W, Yingling JM, Reiss M,. Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. Cancer Res 2008; 68: 1656-1666. (Pubitemid 351416549)
19. Xie W, Bharathy S, Kim D, Haffty BG, Rimm DL, Reiss M,. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res 2003; 14: 61-73. (Pubitemid 38166335)
20. Kim SK, Fan Y, Papadimitrakopoulou V, et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 2519-2521. (Pubitemid 26170686)
21. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L,. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res 1998; 4: 539-544. (Pubitemid 28193551)
22. Takebayashi S, Ogawa T, Jung KY, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 2000; 60: 3397-3403. (Pubitemid 30482154)
23. Bornstein S, White R, Malkoski S, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 2009; 119: 3408-3419.
24. Sirard C, de la Pompa JL, Elia A, et al. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev 1998; 12: 107-119. (Pubitemid 28083662)
25. Iamaroon A, Pattamapun K, Piboonniyom SO,. Aberrant expression of Smad4, a TGF-beta signaling molecule, in oral squamous cell carcinoma. J Oral Sci 2006; 48: 105-109.
26. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847. (Pubitemid 28331029)
27. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958; 53: 457-481.
28. Knobloch TJ, Lynch MA, Song H, et al. Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers. Mutat Res 2001; 479: 131-139. (Pubitemid 32695497)
29. Chen T, Triplett J, Dehner B, et al. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001; 61: 4679-4682. (Pubitemid 32691875)
30. Wang XJ, Greenhalgh DA, Bickenbach JR, et al. Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci U S A 1997; 94: 2386-2391. (Pubitemid 27136884)
31. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M,. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995; 55: 3982-3987.
32. Qiu W, Schonleben F, Li X, Su GH,. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett 2007; 245: 163-170. (Pubitemid 44959352)
33. Garrigue-Antar L, Souza RF, Vellucci VF, Meltzer SJ, Reiss M,. Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab Invest 1996; 75: 263-272. (Pubitemid 26272364)
34. Xie W, Mertens JC, Reiss DJ, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002; 62: 497-505. (Pubitemid 34106424)
35. Buck MB, Fritz P, Dippon J, Zugmaier G, Knabbe C,. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004; 10: 491-498. (Pubitemid 38173987)
36. Parker AS, Lohse CM, Wu K, et al. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol 2007; 38: 453-461. (Pubitemid 46227529)
37. Parker WL, Finnson KW, Soe-Lin H, Knaus P, Philip A,. Expression and function of TbetaRII-B, a variant of the type II TGF-beta receptor, in human chondrocytes. Osteoarthritis Cartilage 2007; 15: 442-453. (Pubitemid 46381569)
38. Takanami I, Tanaka F, Hashizume T, Kodaira S,. Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol 1997; 64: 262-267. (Pubitemid 27190813)
39. Wagner M, Kleeff J, Friess H, Buchler MW, Korc M,. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 1999; 19: 370-376. (Pubitemid 29501433)
40. Lu SL, Herrington H, Reh D, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006; 20: 1331-1342. (Pubitemid 43727593)
41. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E,. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009; 11: 1287-1296.
42. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35. (Pubitemid 350309741)